Abstract 4564
Background
The current standard-of-care first-line therapy for patients (pts) with recurrent/metastatic cervical cancer (r/mCC) is paclitaxel/platinum ± bevacizumab (BEV). However, approximately 50% of pts who are eligible to receive this regimen do not respond to the treatment. Tissue factor (TF) is highly expressed in cervical cancer and is associated with poor prognosis. Tisotumab vedotin (TV) is an investigational first-in-class antibody-drug conjugate comprising a fully human monoclonal antibody targeting TF conjugated to the microtubule-disrupting agent monomethyl auristatin E via a protease-cleavable linker. Single-agent TV demonstrated encouraging antitumor activity (independent review committee–assessed confirmed ORR, 22%; median DOR, 6.0 mo) and a manageable safety profile in pts with previously treated r/mCC. innovaTV 205/ENGOT-cx8 (NCT03786081; GOG-3024) is a global, multicenter, open-label, phase 1/2 trial evaluating the safety and antitumor activity of TV in combination with BEV, pembrolizumab (PEM), or carboplatin (CBP) in pts with untreated and previously treated r/mCC. Results from the innovaTV 205 study will inform the further clinical development of TV in cervical cancer.
Trial design
Approximately 140 adult pts with recurrent or stage IVB squamous, adenosquamous, or adenocarcinoma of the cervix; measurable disease; and ECOG PS 0-1 will be enrolled. The phase 1 portion of the study will consist of 3 dose escalation cohorts for identification of the recommended phase 2 dose (RP2D) of TV with BEV, PEM, or CBP. The phase 2 portion will include 3 expansion cohorts. In the dose escalation cohorts, previously treated pts will receive escalating doses of TV (IV 1Q3W) in combination with escalating doses of BEV (IV 1Q3W), a fixed dose of PEM (IV 1Q3W), or a fixed dose of CBP (IV 1Q3W). In the expansion cohorts, pts who have not received prior systemic therapy for r/mCC will receive 1) TV RP2D + PEM or 2) TV RP2D + CBP; pts who received 1-2 prior treatments for r/mCC will receive TV RP2D + PEM. Additional cohorts might be added. The primary endpoint of phase 2 is ORR (RECIST v1.1). Secondary endpoints include DOR, time to response, PFS, OS, and safety.
Clinical trial identification
NCT03786081; GOG-3024.
Editorial acknowledgement
ApotheCom, San Francisco, CA, USA.
Legal entity responsible for the study
Genmab.
Funding
Genmab.
Disclosure
I.B. Vergote: Advisory / Consultancy: Advaxis; Advisory / Consultancy: Eisai; Advisory / Consultancy: MSD Belgium; Advisory / Consultancy: Roche NV; Advisory / Consultancy, Research grant / Funding (self): Genmab; Advisory / Consultancy: F. Hoffmann-La Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: PharmaMar; Advisory / Consultancy: Millennium; Advisory / Consultancy: Clovis; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro; Advisory / Consultancy, Research grant / Funding (self): Oncoinvent; Advisory / Consultancy: Immunogen; Research grant / Funding (self): Amgen; Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Research grant / Funding (self): Stichting Tegen Kanker; Travel / Accommodation / Expenses: Takeda. N. Concin: Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: AstraZeneca; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Genmab; Travel / Accommodation / Expenses: Amgen. M.R. Mirza: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Biocad; Honoraria (self), Research grant / Funding (institution): Clovis; Honoraria (self): Geneos; Honoraria (self): Genmab; Honoraria (self): Karyopharm; Honoraria (self): Merck; Honoraria (self): Oncology Venture; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Seattle Genetics; Honoraria (self): Sera Prognostics; Honoraria (self): Sotio; Honoraria (self), Research grant / Funding (institution): Tesaro; Honoraria (self): ZaiLab; Research grant / Funding (institution): Boehringer Ingelheim. A. Malmberg: Full / Part-time employment: Genmab. L. Eaton: Full / Part-time employment: Genmab. L. Nicacio: Full / Part-time employment: Seattle Genetics. D. Lorusso: Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Clovis; Advisory / Consultancy: Merrimack. I. Soumaoro: Full / Part-time employment: Genmab. B.J. Monk: Honoraria (self), Advisory / Consultancy, Oncomed (honoraria/consultant): AbbVie; Honoraria (institution), Advisory / Consultancy, Oncoquest (honoraria/consultant): Advaxis; Honoraria (self), Advisory / Consultancy, Oncosec (honoraria/consultant): Agenus; Honoraria (self), Advisory / Consultancy, Perthera (honoraria/consultant): Amgen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Pfizer (honoraria/consultant): AstraZeneca; Honoraria (self), Advisory / Consultancy, Precision Oncology (honoraria/consultant): ChemoCare; Honoraria (self), Advisory / Consultancy, Puma (honoraria/consultant): ChemoID; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Roche/Genentech (honoraria/speaker/consultant): Clovis; Honoraria (self), Advisory / Consultancy, Samumed (honoraria/consultant): Conjupro; Honoraria (self), Advisory / Consultancy, Takeda (honoraria/consultant): Eisai; Honoraria (self), Advisory / Consultancy, Vesaro (honoraria/speaker/consultant): Geistlich; Honoraria (self), Advisory / Consultancy, VBL (honoraria/consultant): Genmab; Honoraria (self), Advisory / Consultancy: ImmunoGen; Honoraria (self), Advisory / Consultancy: Immunomedics; Honoraria (self), Advisory / Consultancy: Incyte; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Janssen/J&J; Honoraria (self), Advisory / Consultancy: Mateon (formerly Oxigene); Honoraria (self), Advisory / Consultancy: Merck; Advisory / Consultancy: Myriad; Honoraria (self), Advisory / Consultancy: Nucana. D.M. O’Malley: Advisory / Consultancy, Research grant / Funding (institution), Officer / Board of Directors, Ergomed Clinical Research (research support - institution): Clovis; Advisory / Consultancy, Research grant / Funding (institution), Exelixis (research support - institution): AstraZeneca; Advisory / Consultancy, Henry Jackson Foundation (research support - institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution), Genentech (research support - institution): Gynecologic Oncology Group; Advisory / Consultancy, GSK (research support - institution): Myriad; Advisory / Consultancy, Research grant / Funding (institution), INC Research (research support - institution): Tesaro; Advisory / Consultancy, inVentiv Health Clinical (research support - institution): Novocure; Advisory / Consultancy, Janssen Research and Development (research support - institution): Translational Genomics/Cordgenics; Officer / Board of Directors, Ludwig Institute for Cancer Research (research support - institution): Novocure; Officer / Board of Directors, Novartis (research support - institution): Amgen; Research grant / Funding (institution), Officer / Board of Directors, PharmaMar (research support - institution): Immunogen; Advisory / Consultancy, Research grant / Funding (institution), Pfizer (research support - institution): AbbVie; Advisory / Consultancy, PRA International (research support - institution): Health Analytics; Advisory / Consultancy, Regeneron (research support - institution): Ambry; Research grant / Funding (institution), Sanofi (research support - institution): Advaxis; Research grant / Funding (institution), Serono (research support - institution): Agenus; Research grant / Funding (institution), Stemcentrx (research support - institution): Ajinomoto; Research grant / Funding (institution), Tracon (research support - institution): Array BioPharma; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Eisai.
Resources from the same session
4317 - Prognostic factors analysis of 343 patients with adenocarcinoma of esophagogastric junction
Presenter: Yixun Lu
Session: Poster Display session 2
Resources:
Abstract
4099 - Effects of preoperative preparation time on efficacy of neoadjuvant chemotherapy (SOX) in patients with advanced gastric cancer
Presenter: Xinxin Wang
Session: Poster Display session 2
Resources:
Abstract
3769 - The prognostic value of higher absolute lymphocyte counts for patients with surgically resected non-advanced gastric cancer
Presenter: Se Jun Park
Session: Poster Display session 2
Resources:
Abstract
1718 - Trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy in resectable HER2+ esophageal adenocarcinoma patients: an update on survival and predictive biomarkers in the TRAP study
Presenter: Charlotte Stroes
Session: Poster Display session 2
Resources:
Abstract
5403 - Interim analysis of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma
Presenter: Thierry Alcindor
Session: Poster Display session 2
Resources:
Abstract
591 - Evaluation of the introduction of primary G-CSF prophylaxis to the FLOT chemotherapy regimen.
Presenter: Kelly-Marie Crampton
Session: Poster Display session 2
Resources:
Abstract
1402 - Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
Presenter: Tsutomu Hayashi
Session: Poster Display session 2
Resources:
Abstract
3743 - HER2 Copy Number as Predictor of Disease-Free Survival in HER2-Positive Resectable Gastric Cancer
Presenter: Zimin Liu
Session: Poster Display session 2
Resources:
Abstract
2032 - Effect of neoadjuvant chemotherapy on the Programmed Death-1 pathway in esophageal and gastric cancer
Presenter: Maria Svensson
Session: Poster Display session 2
Resources:
Abstract
4304 - A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC)
Presenter: Massimiliano Salati
Session: Poster Display session 2
Resources:
Abstract